Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Current Deferred Tax Assets (2016)

Enanta Pharmaceuticals' Current Deferred Tax Assets history spans 3 years, with the latest figure at $1.1 million for Q2 2016.

  • For Q2 2016, Current Deferred Tax Assets fell 34.72% year-over-year to $1.1 million; the TTM value through Jun 2016 reached $1.1 million, down 34.72%, while the annual FY2015 figure was $1.4 million, 86.99% down from the prior year.
  • Current Deferred Tax Assets reached $1.1 million in Q2 2016 per ENTA's latest filing, down from $1.6 million in the prior quarter.
  • In the past five years, Current Deferred Tax Assets ranged from a high of $11.2 million in Q2 2014 to a low of $1.1 million in Q2 2016.
  • Average Current Deferred Tax Assets over 3 years is $3.6 million, with a median of $1.6 million recorded in 2015.
  • The largest YoY upside for Current Deferred Tax Assets was 17.28% in 2015 against a maximum downside of 86.99% in 2015.
  • A 3-year view of Current Deferred Tax Assets shows it stood at $1.3 million in 2014, then rose by 17.28% to $1.6 million in 2015, then fell by 27.45% to $1.1 million in 2016.
  • Per Business Quant, the three most recent readings for ENTA's Current Deferred Tax Assets are $1.1 million (Q2 2016), $1.6 million (Q1 2016), and $1.6 million (Q4 2015).